Minghui Pharmaceutical
明慧医疗
Minghui Pharmaceutical is a late-clinical-stage biopharma company focused on oncology and autoimmune diseases, founded in 2018 by CEO Cao Guoqing . In August 2025, it raised $131 million in a Pre-IPO round co-led by OrbiMed and Qiming Venture Partners, with participation from Taifu Capital, BioTrack Capital, 5Y Capital, and others . The company is developing a pipeline built around a PD-1/VEGF bispecific antibody paired with ADC combinations, plus a topical JAK inhibitor already filed for approval in China and an IGF-1R antibody in Phase III for thyroid eye disease . 5Y Capital described its two ADC assets as showing "best-in-class potential" .
AI-generated — may contain errors, please verify.
Coverage
Qiming Venture Partners and Nearly 40 Portfolio Companies Named to VBData 2026 Future Healthcare 100
China's most authoritative and influential innovation benchmark for the healthcare industry
Seven Qiming Venture Partners Portfolio Companies Named to Cyzone 100 Future Unicorns List
Uncovering the Forces of Business Transformation Over the Next 3–5 Years
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 43, 2025
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies
Morning Star | Over 20 Qiming Venture Partners Portfolio Companies Win 30 Awards in Zero2IPO's 2025 VENTURE50
The VENTURE50 rankings are China's bellwether for high-growth enterprise investment.
